Home / Market timeline
Verified events only · updated Aug 14, 2026
The GLP-1 market timeline, 2024–2027: every event that moved your price
The compounded market's rise, squeeze, and reinvention — plus the two 2026 shocks (an approved pill and Medicare's $50 program) — in one dated line. Every entry traces to a primary source in our catalog; nothing speculative gets a dot.
The legal foundation for mass compounding disappears; wind-down clocks start for 503A (60 days) and 503B pharmacies.
The outsourcing-facility pathway that supplied most telehealth programs closes. Patient-specific 503A compounding with documented clinical need becomes the only lane.
Tirzepatide 20.2% average weight loss vs semaglutide 13.7% at 72 weeks — the first direct trial answer to the market's biggest question.
The first oral semaglutide for obesity reaches the US market — a real pill, with real fasting rules, at roughly $149/month self-pay via NovoCare.
Roughly thirty warning letters hit GLP-1 telehealth marketers still selling outside the patient-specific lane. Compliance posture becomes a consumer-facing issue.
Lilly's non-peptide daily pill becomes the first oral GLP-1 with no food or water restrictions — approved under the FDA's national priority voucher pilot, the first new molecule cleared that way.
Self-pay $149–349/month by dose, $25/month for eligible commercial insurance; retail and telehealth availability follows within days. The 'tirzepatide tablet' question now has an approved — different-molecule — answer.
CMS's demonstration covers Wegovy (injection and tablets), Zepbound KwikPen, and Foundayo for weight management at a $50/month copay for eligible Part D beneficiaries — through Dec 31, 2027. The first Medicare coverage of GLP-1s purely for weight loss.
Semaglutide's Medicare-negotiated price (~$274/month) takes effect and CMS's longer-term BALANCE Model is slated to succeed the Bridge — the next re-pricing of this entire market.